Search results for: Innovation Policy Prize
Filter search results
Performance-Based Risk Sharing in Health Care: Current Status
17 April 2013
…93-102. Towse, A., Garrison, L. and Puig-Peiró, R. (2012) The use of pay-for-performance for drugs: Can it improve incentives for innovation? Occasional Paper. 12/01. London: Office of Health Economics. …
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectiveness Evaluations
25 August 2015
A Research Paper on the topic of incorporating life-cycle price modelling into pharmaceutical cost-effectiveness evaluations has just been published by OHE. Why might the launch price of a new drug…
OHE Lunchtime Seminar on 6 October 2015 PharmaDiplomacy: A Proposal for a Collaborative, Mutually Acceptable Approach to Drug Pricing
22 September 2015
On Tuesday 6th October, James Anderson (GSK), Ri De Ridder (RIZIV-INAMI), and Sophia Tickell (Meteosan) will take part in an OHE seminar to discuss the Checklist for Collaborative, Mutually Acceptable…
Newly Published Analysis: Dementia: the R&D Landscape
16 November 2015
Just published by the World Dementia Council and OHE is an analysis which sets out the dementia R&D landscape. This analysis was undertaken by OHE for Imperial College and the…
How to Manage Data Governance in an Era of Real World Evidence (RWE): Working Towards a Set of International Standards
24 November 2015
A new OHE Consulting Report assesses information governance arrangements for real-world data in eight countries, and makes recommendations towards an ideal governance framework. Real world data (RWD) is a term…
Recently published: Are Wider Societal Effects Considered in Healthcare Decision-making?
29 February 2016
…contact Martina Garau at OHE. Related work: Johannesson, M., Jonsson, B., Jonsson, L., Kobelt, G. and Zethraeus, N., 2009. Why Should Economic Evaluations of Medical Innovations Have a Societal Perspective?…
OHE Lunchtime Seminar on 19 April 2016: Evidence that challenges decision makers: experiences and examples
29 March 2016
…one hand, by the pharmaceutical industry and by patient groups for being too cautious in its approach to appraising medical innovation, and, on the other hand, by NHS managers and…
New publication: The current and future burden of late-onset dementia in the UK: estimates and interventions
10 May 2016
…an intervention to offset the projected increase in DALY burden of dementia in the UK by 2025 appears low”. Dr Matthew Norton, Head of Policy at Alzheimer’s Research UK, said:…
OHE at ISPOR Italy Chapter – Rome: Are Wider Societal Effects Considered in Healthcare Decision-making?
17 May 2016
…Technology Assessment in Health Care, 31(6), pp.449-456. Johannesson, M., Jonsson, B., Jonsson, L., Kobelt, G. and Zethraeus, N., 2009. Why Should Economic Evaluations of Medical Innovations Have a Societal Perspective? …